Amylin Pharmaceuticals, Eli Lilly and Alkermes have announced that exenatide once weekly has been shown to provide superior glucose control when compared to Lantus in a head-to-head duration-3 study.
Patients given exenatide once weekly experienced a statistically superior reduction in A1C (a measure of average blood sugar over three months) of 1.5 percentage points from the baseline, compared to a reduction of 1.3 percentage points for Lantus after 26 weeks of treatment.
Patients treated with exenatide once weekly also showed a statistically significant difference in weight, with a mean weight loss of 5.8 pounds at 26 weeks, compared with a mean weight gain of 3.1 pounds for Lantus, a difference of 8.9 pounds between the treatments.
In addition, patients treated with exenatide once weekly reported significantly fewer episodes of confirmed hypoglycaemia.
Amylin Pharmaceuticals senior vice-president of research and development Orville G Kolterman said that exenatide once weekly outperformed Lantus in this superiority study by meeting its primary endpoint.
"Both treatment arms started with a baseline A1C of 8.3% and exenatide once weekly provided significantly greater A1C reduction, weight loss versus weight gain and fewer episodes of hypoglycaemia," Kolterman said.
More than 90% of patients completed the 26-week study.